Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Access the “What This Means” segment here

BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced it recently participated in a Virtual Investor “What This Means” segment.

For the segment, Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed the Company’s recently issued India Patent No. 562,919 titled, “Thailanstatin Analogs,” covering claims for its potent immuno-oncology PH1 payload, proprietary non-cleavable and cleavable linkers and ADC technology which has applications across various cancer targets.

The ”What This Means” segment is now available here.

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome inhibitor designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. This splicing inhibition has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. Using this novel payload, Akari has the ability to generate multiple ADC molecules based on the desired application to a range of cancer targets of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com